EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium

Andrew G Hadd iD, Angela Silvestro iD, Brittany Avin McKelvey iD, Jonathan Baden, Christina Bormann Chung iD, Ben Brown, Fernando Cruz-Guilloty iD, James Godsey, Gregory Jones, Cheng-Ho Jimmy Lin, Dorys Lopez Ramos iD, Daniel Norton und 7 weitere

Clinical and Translational Science · 2025-03 · 18 (3)

DOI: 10.1111/cts.70185 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 11.03.2025. Verfasst von Andrew G Hadd und 18 weiteren Autor:innen. Beteiligte Einrichtung: Natera, Austin, Texas, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Neoplasm, Residual, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally invasive approach for the identification of circulating tumor biomarkers through a simple blood sample. Assays capable of detecting MRD through analysis of circulating tumor DNA (ctDNA) are rapidly evolving for clinical study applications and therapeutic interventions. To address these opportunities, BLOODPAC—a multi‐disciplinary consortium representing stakeholders from public, industry, academia, and regulatory agencies—formulated a lexicon that provides a shared framework and clear definitions using liquid biopsies for solid tumor MRD with an emphasis on ctDNA detection. The terms in the lexicon are categorized under general MRD, ctDNA testing methodologies, reporting results, and acquisition timepoints, including examples of current and potential clinical use cases for MRD tests. The overall goal is to provide a unified language and approaches to solid tumor MRD to advance applications of these technologies, allow data aggregation to strengthen future evidence, and facilitate regulatory approvals, leading to the use of liquid biopsy as an early endpoint in clinical trials. We believe that a common set of terminology and methods for solid tumor MRD can improve understanding and appropriate use of testing, accelerate clinical development, and improve outcomes for cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNANeoplasm, ResidualBiomarkers, TumorNeoplasmsTerminology as TopicHumansLiquid Biopsy

Stichwörter der Autor:innen

MRDctDNAliquid biopsy

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Natera, Austin, Texas, USA.
  • GSK, Waltham, Massachusetts, USA.
  • Friends of Cancer Research, Washington, DC, USA.
  • Bristol Myers Squibb, Lawrence Township, New Jersey, USA.
  • GRAIL, Inc., Menlo Park, California, USA.
  • Adela Bio, Foster City, California, USA.

ORCID-Profile: Andrew G Hadd, Angela Silvestro, Brittany Avin McKelvey, Christina Bormann Chung, Fernando Cruz-Guilloty, Dorys Lopez Ramos, Thereasa Rich, Mark Stewart, Diana Merino Vega, Lauren C Leiman

Zitieren

APA

Hadd, A. G., Silvestro, A., McKelvey, B. A., Baden, J., Bormann Chung, C., Brown, B., Cruz-Guilloty, F., Godsey, J., Jones, G., Lin, C. J., Lopez Ramos, D., Norton, D., Palomares, M. R., Pena, C., Rich, T., Rodriguez, A., Stewart, M., Merino Vega, D., & Leiman, L. C. (2025). Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium. Clinical and Translational Science, 18(3). https://doi.org/10.1111/cts.70185

Vancouver

Hadd AG, Silvestro A, McKelvey BA, Baden J, Bormann Chung C, Brown B, et al. Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium. Clinical and Translational Science. 2025;18(3). doi:10.1111/cts.70185

BibTeX
@article{Hadd2025,
  author = {Hadd, Andrew G and Silvestro, Angela and McKelvey, Brittany Avin and Baden, Jonathan and Bormann Chung, Christina and Brown, Ben and Cruz-Guilloty, Fernando and Godsey, James and Jones, Gregory and Lin, Cheng-Ho Jimmy and Lopez Ramos, Dorys and Norton, Daniel and Palomares, Melanie R and Pena, Carol and Rich, Thereasa and Rodriguez, Angel and Stewart, Mark and Merino Vega, Diana and Leiman, Lauren C},
  title = {Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {3},
  doi = {10.1111/cts.70185}
}
Kostenlos starten →